Week in Review: Mabwell Bio Raises $547 Million in Shanghai STAR IPO

Deals and Financings   Mabwell ( Shanghai ) Bioscience completed a $547 million IPO on  Shanghai 's STAR Board to develop the 15 assets in its pipeline; Abbisko of Shanghai formed a collaboration with Lilly worth up to $258 million to develop novel drugs for cardiometabolic diseases;  Novotech Health Holdings, a clinical CRO, completed a $255 million financing; it is known as Novotech in Singapore-Australia and PPC in mainland  China ; Suzhou Innovent optioned China rights to develop up to three enzyme inhibitors for inflammatory diseases from Amagma Therapeutics of Massachusetts ; Everest Medicines acquired global rights to several early stage protease inhibitors for SAR-CoV-2 from Singapore 's Experimental Drug Development Centre; Zhejiang JYSS Bio-Engineering closed a B+ round to expand its single use bioreactor and assemblies manufacturing operations; Suzhou Eluminex acquired global rights to a novel oral therapy for childhood blindness and night blindness in early dry AMD from  Seattle 's Retinagenix;  Trials and Approvals   Suzhou CStone Pharma announced its PD-L1 (Cejemly®) met the overall survival endpoint as a first-line therapy for NSCLC in a China Phase III trial; Shanghai Elpiscience started a US Phase I trial of its novel anti-CD39 monoclonal antibody in patients with advanced solid tumors; Neurophth, a Wuhan-San Diego rare disease company, was approved to start US trials of its in-vivo gene replacement therapy for genetic childhood blindness.  Stock Symbols: (SHA: 688062) (HK: 2256) (HK: 01801) (NYSE: LLY) (HK: 1952) (HK: 2616) Share this with colleagues: // //